A phase 1 clinical study of ADVM-062
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Eye disorder therapies (Primary)
- Indications Colour vision defects
- Focus Adverse reactions
- Sponsors Adverum Biotechnologies
- 09 Sep 2024 New trial record
- 29 Aug 2024 According to Blue Gen Therapeutics Foundation media release, company is planning to bring ADVM-062 program to clinic in future.